Highland Bird TherapeuticsNext-generation T-cell engagers for solid tumors.
We develop dual-targeting TCEs and multispecific antibodies for prostate, bladder, kidney and ovarian cancers, with programs in other solid tumors.
Meet our team ↗Integrated antibody engineering and functional screening.
Antibody design
Two tumor targets. Tunable CD3 binding. Flexible antibody formats.
Optimize target pairing, binding kinetics and domain layout. Validate each candidate in relevant models.
Functional screening
Tumor-cell killing, T-cell activation and cytokine release, evaluated over time and dose.
Compare activity and cytokine responses across antigen levels and effector-to-target ratios.
Tumor heterogeneity. Antigen escape. Cytokine release.
Dual-targeting TCEs and multispecific antibodies for solid tumors.
| Program | Indication | Targets | Modality | Research status |
|---|---|---|---|---|
| HB-301Lead program | Prostate cancer | PSMA + X | Dual-tumor-target TCE | Preclinical research |
| HB-302 | Bladder cancer | Nectin-4 + X | Dual-tumor-target TCE | Research focus disclosed* |
| HB-303 | Kidney cancer | IL-2 / PD-1 / X | Multispecific antibody | Research focus disclosed* |
| HB-401 | Ovarian cancer | FRα + X | Dual-tumor-target TCE | Research focus disclosed* |
| HB-402 | Gastrointestinal tumors | CEACAM5 + X | Dual-tumor-target TCE | Research focus disclosed* |
X: undisclosed target. *Detailed stage not disclosed. All programs are investigational.
PSMA + X dual-targeting TCE for prostate cancer. Designed to address tumor heterogeneity and antigen escape. In preclinical development.
Early clinical development, first-in-human studies and China–US regulatory submissions. Previous clinical development roles at Kelun-Biotech and BeiGene.
Protein design, engineering and biological display. Former UCSF postdoctoral researcher. Joined Westlake University in 2019.
Connect with us on research, translation and development.